Media coverage
8
Media coverage
Title Alnylam Presents Positive Complete Results from ENVISION Phase 3 Study of Givosiran, an Investigational RNAi Therapeutic for the Treatment of Acute Hepatic Porphyria Media name/outlet PipelineReview Country/Territory Spain Date 13/04/19 URL www.pipelinereview.com/index.php/2019041371022/DNA-RNA-and-Cells/Alnylam-Presents-Positive-Complete-Results-from-ENVISION-Phase-3-Study-of-Givosiran-an-Investigational-RNAi-Therapeutic-for-the-Treatment-of-Acute-Hepatic-Porphyria.html Persons Manisha Balwani Title Alnylam Presents Positive Complete Results from ENVISION Phase 3 Study of Givosiran, an Investigational RNAi Therapeutic for the Treatment of Acute Hepatic Porphyria Media name/outlet Morningstar.com Country/Territory United States Date 12/04/19 URL https://www.morningstar.com/news/business-wire/BWIPREM_20190412005455/alnylam-presents-positive-complete-results-from-envision-phase-3-study-of-givosiran-an-investigational-rnai-therapeutic-for-the-treatment-of-acute-hepatic-porphyria.html Persons Manisha Balwani Title Alnylam Presents Positive Complete Results from ENVISION Phase 3 Study of Givosiran, an Investigational RNAi Therapeutic for the Treatment of Acute Hepatic Porphyria Media name/outlet India Pharma News Country/Territory India Date 12/04/19 Persons Manisha Balwani Title Alnylam Presents Positive Complete Results from ENVISION Phase 3 Study of Givosiran, an Investigational RNAi Therapeutic for the Treatment of Acute Hepatic Porphyria Media name/outlet Global Banking & Finance Review Country/Territory United Kingdom Date 12/04/19 URL https://www.globalbankingandfinance.com/alnylam-presents-positive-complete-results-from-envision-phase-3-study-of-givosiran-an-investigational-rnai-therapeutic-for-the-treatment-of-acute-hepatic-porphyria/ Persons Manisha Balwani Title Alnylam Presents Positive Complete Results from ENVISION Phase 3 Study of Givosiran, an Investigational RNAi Therapeutic for the Treatment of Acute Hepatic Porphyria Media name/outlet Boerse.de Country/Territory Germany Date 12/04/19 URL https://www.boerse.de/nachrichten/Alnylam-Presents-Positive-Complete-Results-from-ENVISION-Phase-3-Study-of-Givosiran-an-Investigational-RNAi-Therapeutic-for-the-Treatment-of-Acute-Hepatic-Porphyria/8060748 Persons Manisha Balwani Title Alnylam Presents Positive Complete Results from ENVISION Phase 3 Study of Givosiran, an Investigational RNAi Therapeutic for the Treatment of Acute Hepatic Porphyria Media name/outlet Spoke.com Country/Territory United States Date 12/04/19 URL www.spoke.com/press_releases/5cb1128938538a8ff3000ec6 Persons Manisha Balwani Title Alnylam Presents Positive Complete Results from ENVISION Phase 3 Study of Givosiran, an Investigational RNAi Therapeutic for the Treatment of Acute Hepatic Porphyria Media name/outlet FinanzNachrichten.de Country/Territory Germany Date 12/04/19 URL https://www.finanznachrichten.de/nachrichten-2019-04/46456760-alnylam-presents-positive-complete-results-from-envision-phase-3-study-of-givosiran-an-investigational-rnai-therapeutic-for-the-treatment-of-acute-he-004.htm Persons Manisha Balwani Title Alnylam Presents Positive Complete Results from ENVISION Phase 3 Study of Givosiran, an Investigational RNAi Therapeutic for the Treatment of Acute Hepatic Porphyria Media name/outlet VB Profiles Country/Territory United States Date 12/04/19 URL https://www.vbprofiles.com/press_releases/5cb118f094904911b700397e Persons Manisha Balwani